Ikarian Capital, LLC - 30 Sep 2025 SCHEDULE 13G Report for Relmada Therapeutics, Inc. Common Stock, par value $0.001 par value per share (RLMD)

Filing Manager
Ikarian Capital, LLC
Reporting Manager
Ikarian Capital, LLC
Security
Relmada Therapeutics, Inc. Common Stock, par value $0.001 par value per share
Symbol
RLMD
Shares outstanding
73,819,979 shares
Disclosed Ownership
3,543,359 shares
Ownership
4.8%
Form type
SCHEDULE 13G
Filing time
14 Nov 2025, 18:28:02 UTC
Date of event
30 Sep 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Ikarian Capital, LLC disclosed 4.8% ownership in Relmada Therapeutics, Inc. Common Stock, par value $0.001 par value per share (RLMD) on 30 Sep 2025."

Quick Takeaways

  • Ikarian Capital, LLC filed SCHEDULE 13G for Relmada Therapeutics, Inc. Common Stock, par value $0.001 par value per share (RLMD).
  • Disclosed ownership: 4.8%.
  • Date of event: 30 Sep 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 14 Nov 2025, 18:28.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Ikarian Capital, LLC 4.8% 3,543,359 0 3,543,359 /s/ Neil Shahrestani Neil Shahrestani, Sole Manager
Neil Shahrestani 4.8% 3,543,359 0 3,543,359 /s/ Neil Shahrestani Neil Shahrestani

Sponsored